A totally new class of drug just might become a “one-size-fits-all” silver bullet for many neuro-inflammatory conditions.
Developed in the lab of D. Martin Watterson, PhD, at Northwestern University’s Feinberg School of Medicine, the drugs have already been patented, set for commercial development, and safety tested in a Phase 1 human trial.
Neuroinflammation is a type of brain inflammation that seems to be a common denominator in the progressive neurological damage characteristic of diseases such as Alzheimer’s, multiple sclerosis, and Parkinson’s, brain injury, and stroke. And it is thought to play a role in neuro-endocrine-immune conditions such as chronic fatigue syndrome (ME/CFS) and fibromyalgia.
A Novel Treatment Strategy for Alzheimer’s
By addressing neuroinflammation, the new class of drugs – represented by MW151 and MW189 – offers an entirely different therapeutic approach to Alzheimer’s than current ones being tested to prevent the development of beta amyloid plaques